NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results. [electronic resource]
Producer: 20170206Description: 8-9 p. digitalISSN:- 1543-0790
- Antineoplastic Agents -- administration & dosage
- Chemoradiotherapy
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Disease Progression
- Humans
- Intestinal Neoplasms -- diagnosis
- Kaplan-Meier Estimate
- Neuroendocrine Tumors -- diagnosis
- Octreotide -- administration & dosage
- Organometallic Compounds -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.